641 related articles for article (PubMed ID: 27094104)
1. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
2. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
4. Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Liu SY; Wu YL
J Hematol Oncol; 2017 Jul; 10(1):136. PubMed ID: 28679395
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
6. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
7. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
8. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
9. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
10. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
Li X; Lian Z; Wang S; Xing L; Yu J
Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
[TBL] [Abstract][Full Text] [Related]
11. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
13. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
[TBL] [Abstract][Full Text] [Related]
14. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway.
Wang Z; Yuan L; Liao X; Guo X; Chen J
J Med Chem; 2024 Apr; 67(8):6027-6043. PubMed ID: 38598179
[TBL] [Abstract][Full Text] [Related]
15. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Xue S; Hu M; Iyer V; Yu J
J Hematol Oncol; 2017 Apr; 10(1):81. PubMed ID: 28388955
[TBL] [Abstract][Full Text] [Related]
16. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
17. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
18. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
20. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]